Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.

Autor: Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Boissel N; Hématologie Clinique, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France., Papayannidis C; IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia 'Seràgnoli', Bologna, Italy., Luskin MR; Division of Leukemia, Dana-Farber Cancer Institute, Boston, Massachusetts, USA., Stelljes M; Department of Medicine A, Hematology, Oncology, Hemostaseology and Pneumology, University Hospital Münster, Münster, Germany., Advani AS; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA., Jabbour EJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Ribera JM; Clinical Hematology Department, Institut Catalá d'Oncologia-Hospital Germans Trias i Pujol, Jose Carreras Research Institute, Universitat Autonoma de Barcelona, Barcelona, Spain., Marks DI; Bristol Haematology and Oncology Center, University Hospitals Bristol National Health Service Trust, Bristol, UK.

Publikováno v: Cancer [Cancer] 2024 Nov 01; Vol. 130 (21), pp. 3631-3646. Date of Electronic Publication: 2024 Aug 02.

Marks DI, Rowntree C. Management of adults with T-cell lymphoblastic leukemia

Publikováno v: Blood. 129(15)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::338fbbb5f71949e5d2e6eb87c2fd9845
https://pubmed.ncbi.nlm.nih.gov/28115371

Impact of Race and Ethnicity on Outcomes After Umbilical Cord Blood Transplantation.

Autor: Ballen K; Division of Hematology/Oncology, University of Virginia Health System, Charlottesville, Virginia. Electronic address: KB3TC@virginia.edu., Wang T; Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., He N; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin., Knight JM; Section of BMT & Cellular Therapies; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Psychiatry and Behavioral Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin; Department of Microbiology & Immunology, Medical College of Wisconsin, Milwaukee, Wisconsin., Hong S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina., Frangoul H; The Children's Hospital at TriStar Centennial Medical Center, Nashville, Tennessee; Sarah Cannon Research Institute, Nashville, Tennessee., Verdonck LF; Department of Hematology/Oncology, Isala Clinic, Zwolle, The Netherlands., Steinberg A; Westchester Medical Center, Valhalla, New York., Diaz MA; Department of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain., LeMaistre CF; Sarah Cannon, Nashville, Tennessee., Badawy SM; Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois., Pu JJ; VA Boston Medical Center/Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts., Hashem H; Division of Pediatric Hematology/Oncology and Bone Marrow Transplantation, King Hussein Cancer Center, Amman, Jordan., Savani B; Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee., Sharma A; Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee., Lazarus HM; University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio., Abid MB; Divisions of Hematology/Oncology & Infectious Diseases, BMT & Cellular Therapy Program, Medical College of Wisconsin, Milwaukee, Wisconsin., Tay J; Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada., Rangarajan HG; Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation, Nationwide Children's hospital, Columbus, Ohio., Kindwall-Keller T; MetroHealth System, Case Western Reserve University, Cleveland, Ohio., Freytes CO; University of Texas Health Science Center at San Antonio, San Antonio, Texas., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida., Winestone LE; Division of Allergy, Immunology, and Blood & Marrow Transplant, University of California San Francisco Benioff Children's Hospitals, San Francisco, California., Gergis U; Department of Medical Oncology, Division of Hematological Malignancies, Thomas Jefferson University, Philadelphia, Pennsylvania., Farhadfar N; Sarah Cannon Transplant & Cellular Program at Methodist Hospital, San Antonio, Texas., Bhatt NS; University of Washington School of Medicine, Department of Pediatrics, Division of Hematology/Oncology and Bone Marrow Transplant, Seattle, Washington; Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington., Schears RM; University of Central Florida, Department of Emergency Medicine, Orlando, Florida., Gómez-Almaguer D; Hospital Universitario Dr. José E. González, Universidad Autónoma de Nuevo León, Nuevo León, Mexico., Aljurf M; Oncology Center, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia., Agrawal V; Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, California., Kuwatsuka Y; Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan., Seo S; Department of Hematology and Oncology, Dokkyo Medical University, Tochigi, Japan., Marks DI; Bristol Hematology and Oncology Unit, University of Bristol, Bristol, UK., Lehmann L; Dana Farber Cancer Institute/Boston Children's Cancer and Blood Disorders Center, Harvard Medical School, Boston, Massachusetts., Wood WA; Division of Hematology, Department of Medicine, University of North Carolina, Chapel Hill, North Carolina., Hashmi S; Department of Medicine, Sheikh Shakhbout Medical City, Abu Dhabi, UAE; Mayo Clinic Cancer Center, Mayo Clinic, Rochester, Minnesota; College of Medicine and Health Sciences, Khalifa University, Abu Dhabi, UAE., Saber W; CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin.

Publikováno v: Transplantation and cellular therapy [Transplant Cell Ther] 2024 Oct; Vol. 30 (10), pp. 1027.e1-1027.e14. Date of Electronic Publication: 2024 Jul 20.

Results from UKALL60+, a phase 2 study in older patients with untreated acute lymphoblastic leukemia.

Autor: Patel B; Centre for Haemato-Oncology, Barts Cancer Institute Queen Mary University of London London UK., Kirkwood AA; CR UK and UCL Cancer Trial Centre, UCL Cancer Institute, UCL London UK., Rowntree CJ; Cardiff and Vale UHB Cardiff Wales UK., Alapi KZ; Hematology, UCL Cancer Institute London UK., Barretta E; Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute Newcastle University Newcastle Upon Tyne UK., Clifton-Hadley L; CR UK and UCL Cancer Trial Centre, UCL Cancer Institute, UCL London UK., Creasey T; Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute Newcastle University Newcastle Upon Tyne UK., Lee S; Hematology, UCL Cancer Institute London UK., Marks DI; United Bristol Healthcare Trust Bristol UK., Moorman AV; Leukemia Research Cytogenetics Group, Translational and Clinical Research Institute Newcastle University Newcastle Upon Tyne UK., Morley N; Royal Hallamshire Hospital Sheffield Teaching Hospital NHS Foundation Trust Sheffield UK., Patrick P; CR UK and UCL Cancer Trial Centre, UCL Cancer Institute, UCL London UK., Rana Z; CR UK and UCL Cancer Trial Centre, UCL Cancer Institute, UCL London UK., Rijneveld A; Erasmus Medical Centre Rotterdam Netherlands., Snowden JA; Royal Hallamshire Hospital Sheffield Teaching Hospital NHS Foundation Trust Sheffield UK., Fielding AK; Hematology, UCL Cancer Institute London UK.

Publikováno v: HemaSphere [Hemasphere] 2024 Jun 06; Vol. 8 (6), pp. e88. Date of Electronic Publication: 2024 Jun 06 (Print Publication: 2024).

Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel.

Autor: Gökbuget N; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Boissel N; Hospital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Paris, France., Chiaretti S; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Dombret H; Leukemia Department, University Hospital Saint-Louis, Assistance Publique-Hôpitaux de Paris, Saint-Louis Research Institute, Université Paris Cité, Paris, France., Doubek M; Department of Internal Medicine-Hematology and Oncology, University Hospital Brno, Brno, Czech Republic., Fielding A; UCL Cancer Institute, London, United Kingdom., Foà R; Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy., Giebel S; Department of Bone Marrow Transplantation and Onco-Hematology, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland., Hoelzer D; Department of Medicine II, Hematology/Oncology, Goethe University, University Hospital, Frankfurt, Germany., Hunault M; Maladies du Sang University Hospital of Angers, FHU Goal, INSERM, National Centre for Scientific Research, Angers, France., Marks DI; University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom., Martinelli G; IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori, Meldola, Italy., Ottmann O; Division of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, United Kingdom., Rijneveld A; Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Rousselot P; Clinical Hematology Department, Centre Hospitalier de Versailles, Université Paris-Saclay, Versailles, France., Ribera J; Clinical Hematology Department, Institut Catala d'Oncologia-Hospital Germans Trias I Pujol, Josep Carreras Research Institute, Badalona, Spain., Bassan R; Division of Hematology, Ospedale dell'Angelo, Mestre-Venice, Italy.

Publikováno v: Blood [Blood] 2024 May 09; Vol. 143 (19), pp. 1891-1902.